WPD Pharmaceuticals（WBIO）株式概要WPDファーマシューティカルズ社には重要な事業はない。 詳細WBIO ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析収益が 100 万ドル未満 ( CA$0 )マイナスの株主資本 意味のある時価総額がありません ( CA$325K )株式の流動性は非常に低い +1 さらなるリスクすべてのリスクチェックを見るWBIO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.07該当なし内在価値ディスカウントEst. Revenue$PastFuture-16m6m2016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesWPD Pharmaceuticals Inc. 競合他社Vaxil BioSymbol: TSXV:VXLMarket cap: CA$896.4kEntheon BiomedicalSymbol: CNSX:ENBIMarket cap: CA$1.4mCytophage TechnologiesSymbol: TSXV:CYTOMarket cap: CA$338.4kPsyence GroupSymbol: CNSX:PSYGMarket cap: CA$1.9m価格と性能株価の高値、安値、推移の概要WPD Pharmaceuticals過去の株価現在の株価CA$0.0752週高値CA$0.5052週安値CA$0.07ベータ0.221ヶ月の変化0%3ヶ月変化n/a1年変化-44.00%3年間の変化-93.78%5年間の変化-99.31%IPOからの変化-99.53%最新ニュースNew Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$259k free cash flow). Shares are highly illiquid. Negative equity (-CA$714k). Revenue is less than US$1m. Market cap is less than US$10m (CA$579.9k market cap, or US$419.3k). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).お知らせ • May 31WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024. Location: british columbia, vancouver CanadaBoard Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Peter Novak was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 16WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in fundingOn June 15, 2023, WPD Pharmaceuticals Inc. closed the transaction. Each Debenture is convertible into units at a conversion price of CAD 0.05 per Unit. Each Unit will consist of one common share and one share purchase warrant exercisable to purchase one additional common share at a price of CAD 0.05 for three years from the date of issuance of the Unit. The Debentures bear interest at the rate of 18% per annum compounded monthly until maturity and after default. The Debentures will mature on June 2, 2026. There were no finder’s fees paid in connection with the Private Placement. All securities issued in the Private Placement will be subject to a four-month hold period commencing on the closing date of the Private Placement.お知らせ • Jan 20WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line TherapyWPD Pharmaceuticals Inc. announced that the first patient enrolled in the Phase 1B/2 clinical trial of intravenously infused Berubicin in the treatment of adult patients with recurrent glioblastoma multiforme after failure of standard first line therapy, has received the first dosing of Berubicin. This is a very important step in Berubicin clinical development. WPD Pharmaceuticals has initiated multicenter, open-label, Phase 1B/2 efficacy and safetystudy of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose identified in Phase 1 studies, on the endpoint of ORR in up toapproximately 61 patients. Four polish clinical sites have been contracted for purpose of this clinical trials. A central reader will determine the radiologic responses for each patient according to m-RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin, was developed by Dr. Waldemar Priebe. Phase 1 clinical trial previously conducted by Reata Pharmaceuticals Inc. demonstrated positive responses after Berubicin treatment of brain cancer patients with one durable complete response.Is New 90 Day High Low • Jan 05New 90-day high: CA$0.31The company is up 27% from its price of CA$0.24 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.最新情報をもっと見るRecent updatesNew Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$259k free cash flow). Shares are highly illiquid. Negative equity (-CA$714k). Revenue is less than US$1m. Market cap is less than US$10m (CA$579.9k market cap, or US$419.3k). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).お知らせ • May 31WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024. Location: british columbia, vancouver CanadaBoard Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Peter Novak was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jun 16WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in fundingOn June 15, 2023, WPD Pharmaceuticals Inc. closed the transaction. Each Debenture is convertible into units at a conversion price of CAD 0.05 per Unit. Each Unit will consist of one common share and one share purchase warrant exercisable to purchase one additional common share at a price of CAD 0.05 for three years from the date of issuance of the Unit. The Debentures bear interest at the rate of 18% per annum compounded monthly until maturity and after default. The Debentures will mature on June 2, 2026. There were no finder’s fees paid in connection with the Private Placement. All securities issued in the Private Placement will be subject to a four-month hold period commencing on the closing date of the Private Placement.お知らせ • Jan 20WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line TherapyWPD Pharmaceuticals Inc. announced that the first patient enrolled in the Phase 1B/2 clinical trial of intravenously infused Berubicin in the treatment of adult patients with recurrent glioblastoma multiforme after failure of standard first line therapy, has received the first dosing of Berubicin. This is a very important step in Berubicin clinical development. WPD Pharmaceuticals has initiated multicenter, open-label, Phase 1B/2 efficacy and safetystudy of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose identified in Phase 1 studies, on the endpoint of ORR in up toapproximately 61 patients. Four polish clinical sites have been contracted for purpose of this clinical trials. A central reader will determine the radiologic responses for each patient according to m-RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin, was developed by Dr. Waldemar Priebe. Phase 1 clinical trial previously conducted by Reata Pharmaceuticals Inc. demonstrated positive responses after Berubicin treatment of brain cancer patients with one durable complete response.Is New 90 Day High Low • Jan 05New 90-day high: CA$0.31The company is up 27% from its price of CA$0.24 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Oct 02New 90-day low: CA$0.24The company is down 41% from its price of CA$0.41 on 03 July 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.株主還元WBIOCA BiotechsCA 市場7D0%11.0%2.5%1Y-44.0%21.5%32.5%株主還元を見る業界別リターン: WBIO過去 1 年間で21.5 % の収益を上げたCanadian Biotechs業界を下回りました。リターン対市場: WBIOは、過去 1 年間で32.5 % のリターンを上げたCanadian市場を下回りました。価格変動Is WBIO's price volatile compared to industry and market?WBIO volatilityWBIO Average Weekly Movementn/aBiotechs Industry Average Movement11.1%Market Average Movement10.2%10% most volatile stocks in CA Market17.8%10% least volatile stocks in CA Market3.8%安定した株価: WBIOの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のWBIOのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aMariusz Olejniczakwww.wpdpharmaceuticals.comWPDファーマシューティカルズ・インクには重要な事業はない。以前はがん領域の医薬品の研究開発に従事していた。本社はカナダのバンクーバー。もっと見るWPD Pharmaceuticals Inc. 基礎のまとめWPD Pharmaceuticals の収益と売上を時価総額と比較するとどうか。WBIO 基礎統計学時価総額CA$324.76k収益（TTM）-CA$6.71k売上高(TTM)n/a0.0xP/Sレシオ-48.4xPER（株価収益率WBIO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計WBIO 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$6.71k収益-CA$6.71k直近の収益報告Sep 30, 2024次回決算日該当なし一株当たり利益（EPS）-0.0014グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-62.8%WBIO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/05 17:49終値2025/05/08 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋WPD Pharmaceuticals Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$259k free cash flow). Shares are highly illiquid. Negative equity (-CA$714k). Revenue is less than US$1m. Market cap is less than US$10m (CA$579.9k market cap, or US$419.3k). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
お知らせ • May 31WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024. Location: british columbia, vancouver Canada
Board Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Peter Novak was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 16WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in fundingOn June 15, 2023, WPD Pharmaceuticals Inc. closed the transaction. Each Debenture is convertible into units at a conversion price of CAD 0.05 per Unit. Each Unit will consist of one common share and one share purchase warrant exercisable to purchase one additional common share at a price of CAD 0.05 for three years from the date of issuance of the Unit. The Debentures bear interest at the rate of 18% per annum compounded monthly until maturity and after default. The Debentures will mature on June 2, 2026. There were no finder’s fees paid in connection with the Private Placement. All securities issued in the Private Placement will be subject to a four-month hold period commencing on the closing date of the Private Placement.
お知らせ • Jan 20WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line TherapyWPD Pharmaceuticals Inc. announced that the first patient enrolled in the Phase 1B/2 clinical trial of intravenously infused Berubicin in the treatment of adult patients with recurrent glioblastoma multiforme after failure of standard first line therapy, has received the first dosing of Berubicin. This is a very important step in Berubicin clinical development. WPD Pharmaceuticals has initiated multicenter, open-label, Phase 1B/2 efficacy and safetystudy of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose identified in Phase 1 studies, on the endpoint of ORR in up toapproximately 61 patients. Four polish clinical sites have been contracted for purpose of this clinical trials. A central reader will determine the radiologic responses for each patient according to m-RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin, was developed by Dr. Waldemar Priebe. Phase 1 clinical trial previously conducted by Reata Pharmaceuticals Inc. demonstrated positive responses after Berubicin treatment of brain cancer patients with one durable complete response.
Is New 90 Day High Low • Jan 05New 90-day high: CA$0.31The company is up 27% from its price of CA$0.24 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.
New Risk • Jul 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$259k free cash flow). Shares are highly illiquid. Negative equity (-CA$714k). Revenue is less than US$1m. Market cap is less than US$10m (CA$579.9k market cap, or US$419.3k). Minor Risk Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
お知らせ • May 31WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024WPD Pharmaceuticals Inc., Annual General Meeting, Aug 07, 2024. Location: british columbia, vancouver Canada
Board Change • May 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Peter Novak was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 16WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in fundingOn June 15, 2023, WPD Pharmaceuticals Inc. closed the transaction. Each Debenture is convertible into units at a conversion price of CAD 0.05 per Unit. Each Unit will consist of one common share and one share purchase warrant exercisable to purchase one additional common share at a price of CAD 0.05 for three years from the date of issuance of the Unit. The Debentures bear interest at the rate of 18% per annum compounded monthly until maturity and after default. The Debentures will mature on June 2, 2026. There were no finder’s fees paid in connection with the Private Placement. All securities issued in the Private Placement will be subject to a four-month hold period commencing on the closing date of the Private Placement.
お知らせ • Jan 20WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line TherapyWPD Pharmaceuticals Inc. announced that the first patient enrolled in the Phase 1B/2 clinical trial of intravenously infused Berubicin in the treatment of adult patients with recurrent glioblastoma multiforme after failure of standard first line therapy, has received the first dosing of Berubicin. This is a very important step in Berubicin clinical development. WPD Pharmaceuticals has initiated multicenter, open-label, Phase 1B/2 efficacy and safetystudy of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose identified in Phase 1 studies, on the endpoint of ORR in up toapproximately 61 patients. Four polish clinical sites have been contracted for purpose of this clinical trials. A central reader will determine the radiologic responses for each patient according to m-RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline. Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin, was developed by Dr. Waldemar Priebe. Phase 1 clinical trial previously conducted by Reata Pharmaceuticals Inc. demonstrated positive responses after Berubicin treatment of brain cancer patients with one durable complete response.
Is New 90 Day High Low • Jan 05New 90-day high: CA$0.31The company is up 27% from its price of CA$0.24 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Oct 02New 90-day low: CA$0.24The company is down 41% from its price of CA$0.41 on 03 July 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.
